Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9409678 | 0.78 | TBXAS1 (0.38) | TBXAS1 | |
| SCHEMBL9409686 | 0.77 | TBXAS1 (0.43) | TBXAS1KDM4EALDH1A1 | |
| SCHEMBL9029648 | 0.75 | CHRM2 (0.56) | ALDH1A1 | |
| SCHEMBL9299603 | 0.75 | CHRM2 (0.57) | — | |
| SCHEMBL9409682 | 0.73 | — | — | |
| SCHEMBL8847585 | 0.72 | TBXAS1 (0.43) | TBXAS1KDM4EALDH1A1 | |
| SCHEMBL9409697 | 0.72 | CHRM2 (0.45) | — | |
| SCHEMBL9409683 | 0.72 | CHRM2 (0.33) | ALDH1A1 | |
| SCHEMBL9826154 | 0.71 | PER2 (0.32) | ALDH1A1 | |
| SCHEMBL9029545 | 0.71 | TBXAS1 (0.47) | TBXAS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305078-A1 | TYPE I PHOTOINITIATOR FOR CROSSLINKING SILICONE COMPOSITIONS | Elkem Silicones France SAS (FR) | 2024-01-17 | — | — | EP | claimed |
| EP-4274856-A1 | RADIATION CROSS-LINKABLE SILICONE COMPOSITION COMPRISING AN ADHERENCE MODULATOR | Elkem Silicones France SAS (FR) | 2023-11-15 | — | — | EP | claimed |
| EP-0629395-A1 | Keratinous fiber treatment compositions | Kao Corporation (JP) | 1994-12-21 | — | — | EP | claimed |
| EP-0605393-A1 | Heterocyclic acetylenic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1994-07-06 | — | — | EP | claimed |
| WO-1990004588-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-05-03 | — | — | WO | claimed |
| EP-4305078-A1 | TYPE I PHOTOINITIATOR FOR CROSSLINKING SILICONE COMPOSITIONS | Elkem Silicones France SAS (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-4274856-A1 | RADIATION CROSS-LINKABLE SILICONE COMPOSITION COMPRISING AN ADHERENCE MODULATOR | Elkem Silicones France SAS (FR) | 2023-11-15 | — | — | EP | disclosed |
| CN-116324409-A | Substrate for producing sensor for analysis of detection object, and analysis method of detection object | 国立大学法人神户大学 | 2023-06-23 | — | — | CN | disclosed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | disclosed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | disclosed |
| EP-2481408-A2 | New use of glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | disclosed |
| WO-2008104580-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-09-04 | — | — | WO | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| EP-0605393-A1 | Heterocyclic acetylenic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1994-07-06 | — | — | EP | disclosed |
| US-5225567-A | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| US-5157124-A | Improving mental performance | THE UPJOHN COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| US-5137905-A | Cholinergic agonists; analgesics; cognition activators | THE UPJOHN COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| WO-1990004588-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLUL | TBXAS1 1741/4885KDM4E 3719/4885ALDH1A1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.